213 related articles for article (PubMed ID: 34714120)
21. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study.
Cutler AJ; Suzuki K; Starling B; Balakrishnan K; Komaroff M; Castelli M; Meeves S; Childress AC
J Child Adolesc Psychopharmacol; 2022 Mar; 32(2):89-97. PubMed ID: 35020462
[No Abstract] [Full Text] [Related]
23. Gender Effects in the Efficacy of Racemic Amphetamine Sulfate in Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Newcorn JH; Cutler AJ
Adv Ther; 2019 Jun; 36(6):1370-1387. PubMed ID: 30972657
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
Faraone SV; Childress AC; Gomeni R; Rafla E; Kando JC; Dansie L; Naik P; Pardo A
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):14-19. PubMed ID: 36730749
[No Abstract] [Full Text] [Related]
25. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
Wigal S; Lopez F; Frick G; Yan B; Robertson B; Madhoo M
Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017
[TBL] [Abstract][Full Text] [Related]
26. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
[No Abstract] [Full Text] [Related]
27. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
28. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
[No Abstract] [Full Text] [Related]
29. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237
[TBL] [Abstract][Full Text] [Related]
30. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
31. Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.
Shram MJ; Setnik B; Webster L; Guenther S; Mickle TC; Braeckman R; Kanski J; Martin A; Kelsh D; Vince BD; Barrett AC
Curr Med Res Opin; 2022 Jul; 38(7):1237-1250. PubMed ID: 35570699
[TBL] [Abstract][Full Text] [Related]
32. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
Jain R; Babcock T; Burtea T; Dirks B; Adeyi B; Scheckner B; Lasser R; Renna J; Duncan D
Adv Ther; 2013 May; 30(5):472-86. PubMed ID: 23681505
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study.
Wigal SB; Hopkins SC; Koblan KS; Childress A; Kent JM; Tsai J; Hsu J; Loebel A; Goldman R
J Atten Disord; 2020 Jan; 24(2):192-204. PubMed ID: 31375051
[No Abstract] [Full Text] [Related]
35. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
36. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
[TBL] [Abstract][Full Text] [Related]
37. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
Wigal SB; Gupta S; Heverin E; Starr HL
J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
[TBL] [Abstract][Full Text] [Related]
39. Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study.
Cutler AJ; Kollins SH; Brams MN; Corliss M; Oh C; Braeckman R; Childress AC
Front Psychiatry; 2024; 15():1310483. PubMed ID: 38566957
[TBL] [Abstract][Full Text] [Related]
40. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
Huss M; Ginsberg Y; Arngrim T; Philipsen A; Carter K; Chen CW; Gandhi P; Kumar V
Clin Drug Investig; 2014 Sep; 34(9):639-49. PubMed ID: 25015027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
